RECITALS:Product Development and License Agreement • September 6th, 2005 • Elite Pharmaceuticals Inc /De/ • Pharmaceutical preparations • New Jersey
PRODUCT DEVELOPMENT AND LICENSE AGREEMENTProduct Development and License Agreement • July 18th, 2007 • Amedica Corp • Surgical & medical instruments & apparatus • Delaware
THIS PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”) is made and entered into this 20th day of December, 2006 (“Effective Date”), by and between AMEDICA CORPORATION, having its principal offices at 615 Arapeen Drive, Salt Lake City, Utah 84108 (“AMEDICA”), and DYTECH CORPORATION LTD, having its principal offices at Stopes Road, Stannington, Sheffield, S6 6BW England (“DYTECH”).
RECITALSProduct Development and License Agreement • December 27th, 2005 • Authentidate Holding Corp • Services-computer integrated systems design • Colorado
FIRST AMENDMENT DATED AS OF DECEMBER 4, 2006 TO PRODUCT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN NASTECH PHARMACEUTICAL COMPANY INC. AND PROCTER & GAMBLE PHARMACEUTICALS, INC. DATED AS OF JANUARY 27, 2006Product Development and License Agreement • March 7th, 2007 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
This First Amendment to the Product Development and License Agreement (the “First Amendment”) is entered into as of December 4, 2006 by and between PROCTER & GAMBLE PHARMACEUTICALS, INC., a corporation organized under the laws of Ohio (“P&G”), and NASTECH PHARMACEUTICAL COMPANY INC., a corporation organized under the laws of Delaware (“Nastech”), as an amendment to the Product Development and License Agreement (the “Agreement”) entered into as of January 27, 2006 by and between P&G and Nastech. All capitalized terms used herein shall have the meanings given in the Agreement.
PRODUCT DEVELOPMENT AND LICENSE AGREEMENTProduct Development and License Agreement • September 15th, 2004 • Bionutrics Inc • Medicinal chemicals & botanical products • New York
This license agreement (the “Agreement”) dated as of June 16, 2004 (the “Effective Date”) is entered into by and between Nostrum Pharmaceuticals, Inc. (“Nostrum”), a Delaware corporation, and Bionutrics, Inc. (“Bionutrics”), a Nevada corporation.
PRODUCT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN NASTECH PHARMACEUTICAL COMPANY INC. AND PROCTER & GAMBLE PHARMACEUTICALS, INC. DATED AS OF JANUARY 27, 2006Product Development and License Agreement • February 2nd, 2006 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New York
This Product Development and License Agreement (the “Agreement”) is entered into as of January 27, 2006 by and between PROCTER & GAMBLE PHARMACEUTICALS, INC., a corporation organized under the laws of Ohio (“P&G”), and NASTECH PHARMACEUTICAL COMPANY INC., a corporation organized under the laws of Delaware (“Nastech”).
AMENDMENT TO PRODUCT DEVELOPMENT AND LICENSE AGREEMENTProduct Development and License Agreement • May 7th, 2009 • Shire PLC • Pharmaceutical preparations
This Amendment to the Product Development and License Agreement, effective as of February 24, 2009, is by and between Shire LLC, Shire Biopharmaceuticals Holdings (formerly known as Shire plc) (collectively “Shire”) and Duramed Pharmaceuticals, Inc. (“Duramed”). Shire and Duramed are referred to together as the “Parties”.
PRODUCT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN DYAX CORP. AND CMIC CO. LTD. DATED AS OF SEPTEMBER 28, 2010 Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission.Product Development and License Agreement • November 2nd, 2010 • Dyax Corp • Services-commercial physical & biological research • Massachusetts
